MELBOURNE, Australia - Taking sick days is set to get tougher -- there may be a cure for the common cold.
Australian drug maker Biota Wednesday reported the stunning success of its antiviral compound, named Vapendavir.
Tested
in 300 asthmatic patients infected with the cold-causing human
rhinovirus, the clinical trial showed that cold symptoms eased quickly
and the duration of the infection was shortened considerably.
Patients
given a placebo experienced the worst cold symptoms at 2.5 days,
whereas those dosed with Vapendavir began rapid recovery after just 1.7
days. More here:

No comments:
Post a Comment